Viz.ai has announced clinical data validating the impact of Viz LVO in the management and outcomes of patients with large vessel occlusion (LVO) ischaemic stroke. Viz LVO—part of the Viz Neuro suite of artificial intelligence (AI)-powered solutions—automatically detects and triages suspected LVO patients, and has been shown to reduce delays in acute stroke treatment.
A real-world study now published in the journal Interventional Neuroradiology evaluated the clinical impact of Viz LVO on the rate of transfers resulting in endovascular thrombectomy and associated costs before and after implementation of an AI-based software. The study found that implementation of the Viz LVO software significantly increased computed tomography angiography (CTA) use and led to a 14% rise in transfers treated with thrombectomy—with an associated increase in spoke revenue and potentially lower payer costs.
“Our findings highlight the efficacy and practical application of AI in a clinical setting,” said James Bonner (Inspira Medical Center Mullica Hill, Harrison Township, USA). “We are proud to partner with Viz.ai and utilise their innovative solutions to continue advancing the management of patients with LVOs where every minute counts. The care that the spoke hospitals can deliver has been significantly enhanced by real-time, actionable data that Viz.ai has delivered for us.”
A recent press release from Viz.ai notes that the transfer of an ischaemic stroke patient with suspected LVO who does not undergo thrombectomy at a comprehensive stroke centre (CSC)—sometimes referred to as a futile transfer—is taxing on providers, costly to healthcare systems, and displaces patients from their families. This study demonstrated the impact of implementing the company’s AI-based system, which allowed the care team at the hub and spokes to quickly and reliably access, review, and comment on, both non-contrast and contrast CT scans with automated alerts for suspected LVO.
“The findings from this study represent a crucial advancement in our continuous effort to enhance patient outcomes and reduce healthcare costs through AI,” said Prem Batchu-Green, vice president of Clinical at Viz.ai. “By demonstrating the real-world benefits of Viz LVO on essential metrics like transfers, we are not only confirming the efficacy of our technology but also reinforcing our dedication to making a significant impact in healthcare for the betterment of patients, their caregivers, and healthcare teams.”
